Expression of caveolin-1 in peritumoral stroma is associated with histological grade in ovarian serous tumors

Ginekologia Polska

Volumn 86, Issue 6, 2015, Pages 424-428

  Sayhan, Sevil ^a   Diniz, Gulden ^a   Karadeniz, Tugba ^a   Ayaz, Duygu ^a   Kahraman, Dudu Solakoglu ^a   Gokcu, Mehmet ^a   Yildirim, Hulya Tosun ^b  

^a Tepecik Research and Training Hospital   (Turkey)

^b DR BEHÇET UZ CHILDREN'S HOSPITAL   (Turkey)

Author keywords

Caveolin 1; Ovary; Serous tumors

Indexed keywords

CAVEOLIN 1;

ADULT; AGED; CANCER GRADING; CANCER STAGING; CYSTADENOCARCINOMA; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; PROGNOSIS; YOUNG ADULT;

ADULT; AGED; CAVEOLIN 1; CYSTADENOCARCINOMA, SEROUS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; YOUNG ADULT;

EID: 84939495977     PISSN: 00170011     EISSN: None     Source Type: Journal    
DOI: 10.17772/gp/2398     Document Type: Article

References (22)

1. Senetta R, Stella G, Pozzi E, [et al.]. Caveolin-1 as a promoter of tumour spreading: when, how, where and why. J Cell Mol Med. 2013, 17 (3), 325-336. [doi: 10.1111/jcmm.12030].
2. Engelman JA, Zhang X, Galbiati F, [et al.]. Molecular genetics of the caveolin gene family:implications for human cancers, diabetes, Alzheimer disease, and muscular dystrophy. Am J Hum Genet. 1998, 63 (6), 1578-1587.
3. Ayala G, Morello M, Frolov A, [et al.]. Loss of Caveolin-1 in prostate cancer stroma correlates with reduced relapse-free survival and is functionally relevant to tumour progression. J Pathol.2013, 231 (1), 77-87.
4. Sáinz-Jaspeado M, Martin-Liberal J, Lagares-Tena L, [et al.]. Caveolin-1 in sarcomas: friend or foe? Oncotarget. 2011, 2 (4), 305-312.
5. Vang R, Shih IeM, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma:pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol. 2009, 16 (5), 267-282.
6. Kurman RJ, Shih IeM. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol. 2008, 27 (2), 151-160.
7. Carter J, Fowler J, Carlson J, [et al.]. Borderline and invasive epithelial ovarian tumors in young women. Obstet Gynecol. 1993, 82 (5), 752-756.
8. Rosai J. Ovary. In: Rosai and Ackerman's Surgical Pathology. (Eds). Rosai J 10. Ed. Philadelphia:Mosby Elsevier. 2011, Vol 2, 1553-1635.
9. Davidson B, Nesland JM, Goldberg I, [et al.]. Caveolin-1 expression in advanced- stage ovarian carcinoma: a clinicopathologic study. Gynecol Oncol. 2001, 81 (2), 166-171.
10. Davidson B, Goldberg I, Givant-Horwitz V, [et al.]. Caveolin-1 expression in ovarian carcinoma is MDR1 independent. Am J Clin Pathol. 2002, 117 (2), 225-234.
11. Wiechen K, Diatchenko L, Agoulnik A, [et al.]. Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Am J Pathol. 2001, 159 (5), 1635-1643.
12. Campbell L, Gumbleton M, Griffiths DF. Caveolin-1 overexpression predicts poor disease-free survival of patients with clinically confined renal cell carcinoma. Br J Cancer. 2003, 89 (10), 1909-1913.
13. Basu Roy UK, Henkhaus RS, Loupakis F, [et al.]. Caveolin-1 is a novel regulator of K-RASdependent migration in colon carcinogenesis.Int J Cancer. 2013, 133 (1), 43-57.
14. Li L, Ren CH, Tahir SA, [et al.]. Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol Cell Biol. 2003, 23, 9389-9404.
15. Rossi S, Poliani PL, Cominelli M, [et al.]. Caveolin-1 is a marker of poor differentiation in Rhabdomyosarcoma. Eur J Cancer. 2011, 47 (5), 761-772.
16. Quann K, Gonzales DM, Mercier I, [et al.]. Caveolin-1 is a negative regulator of tumor growth in glioblastoma and modulates chemosensitivity to temozolomide. Cell Cycle. 2013, 12 (10), 1510-1520.
17. Paskaš S, Janković J, Marečko I, [et al.]. Caveolin-1 expression in papillary thyroid carcinoma:correlation with clinicopathological parameters and BRAF mutation status. Otolaryngol Head Neck Surg. 2014, 150 (2), 201-209.
18. Tuxhorn JA, McAlhany SJ, Dang TD, [et al.]. Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model. Cancer Res. 2002, 62 (11), 3298-3307.
19. Faggi F, Mitola S, Sorci G, [et al.]. Phosphocaveolin-1 enforces tumor growth and chemoresistance in rhabdomyosarcoma. PLoS One. 2014, 9 (1), e84618. [doi: 10.1371/ journal.pone.0084618].
20. Goetz JG, Minguet S, Navarro-Lérida I, [et al.]. Biomechanical remodeling of the microenvironment by stromal Caveolin-1 favors tumor invasion and metastasis. Cell. 2011, 146 (1), 148-163.
21. Witkiewicz AK, Dasgupta A, Sotgia F, [et al.]. An absence of stromal Caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol. 2009, 174 (6), 2023-2034.
22. Wu KN, Queenan M, Brody JR, [et al.]. Loss of stromal Caveolin-1 expression in malignant melanoma metastases predicts poor survival. Cell Cycle. 2011, 10 (24), 4250-4255.